Literature DB >> 16671908

Inhibitory effects of Triptolide on interferon-gamma-induced human leucocyte antigen-DR, intercellular adhesion molecule-1, CD40 expression on retro-ocular fibroblasts derived from patients with Graves' ophthalmopathy.

Shu-Xun Yan1, Ying Wang.   

Abstract

PURPOSE: To explore the effects of Triptolide, the principal active diterpenoid from the Chinese Medicinal Herb Tripterygium Wilfordii Hook F that has immunosuppressive and anti-inflammatory properties, on cell proliferation, hyaluronic acid (HA) synthesis, and the expressions of human leucocyte antigen-DR (HLA-DR), intercellular adhesion molecule-1 (ICAM-1) and CD40 on cultured retro-ocular fibroblasts (RFs) from patients with Graves' ophthalmopathy.
METHODS: After two to five passages, cultured RFs were incubated for 48 h within a medium alone or in the presence of recombinant human interferon-gamma (IFN-gamma) and various concentrations of Triptolide. Cell viability was assessed by MTT (3-[4.5-dimethylahiazol-2-yl]-2,5-diphenyltetrazolium Bromide). RFs proliferation was assessed by [(3)H]-thymidine incorporation assay. Flow cytometry was used to investigate the amount of HLA-DR, ICAM-1 and CD40. HA synthesis was measured by radioimmunoassay.
RESULTS: Cell viability was not detrimentally affected when incubated with Triptolide from 0.01 microg/L to 10 microg/L for 48 h, and decreased with 20 microg/L Triptolide. The incorporation of [(3)H]-thymidine of RFs was 55 476 +/- 15 842 cpm incubated with medium alone or 18 352 +/- 3568 cpm with 10 microg/L Triptolide (t = 5.600, P < 0.01). Initially, the percentage of positive cells of HLA-DR, ICAM-1 and CD40 on RFs were 4.75 +/- 2.13%, 17.53 +/- 10.12% and 6.38 +/- 2.23%, respectively, and the synthesis of HA was 100 +/- 12%. Compared with basal values, 48-h incubation with IFN-gamma (100 U/mL) significantly enhanced the amount of HLA-DR, ICAM-1 and CD40, and HA synthesis. The values were 60.58 +/- 10.12% (t = 13.224, P < 0.01), 62.66 +/- 18.17% (t = 5.315, P < 0.01), 57.67 +/- 13.61% (t = 9.110, P < 0.01) and 164 +/- 22% (t = 9.238, P < 0.01), respectively. Triptolide 0.01 microg/L had little effect on IFN-gamma-induced HLA-DR, ICAM-1 and CD40 amounts, as well as HA synthesis. When the concentration ranged from 0.1 microg/L to 10 microg/L, Triptolide inhibited IFN-gamma-induced RFs activation in a dose-dependent manner. It was also found that Triptolide had the same inhibiting effects on IFN-gamma-induced RFs and skin fibroblasts from patients with normal individual conditions.
CONCLUSIONS: Triptolide could inhibit IFN-gamma-induced activation of RFs derived from patients with Graves' ophthalmopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16671908     DOI: 10.1111/j.1442-9071.2006.01190.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  8 in total

Review 1.  Action mechanisms of complementary and alternative medicine therapies for rheumatoid arthritis.

Authors:  Imada Keisuke; Bao-lin Bian; Xiang-dong Li; Sato Takashi; Ito Akira
Journal:  Chin J Integr Med       Date:  2011-10       Impact factor: 1.978

2.  Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer.

Authors:  Sulagna Banerjee; Shrey Modi; Olivia McGinn; Xianda Zhao; Vikas Dudeja; Sundaram Ramakrishnan; Ashok K Saluja
Journal:  Clin Cancer Res       Date:  2015-09-24       Impact factor: 12.531

Review 3.  Immunoregulatory effects of Tripterygium wilfordii Hook F and its extracts in clinical practice.

Authors:  Dan Luo; Zhengyun Zuo; Hongyan Zhao; Yong Tan; Cheng Xiao
Journal:  Front Med       Date:  2019-01-02       Impact factor: 4.592

Review 4.  Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment.

Authors:  Sita Virakul; Leendert van Steensel; Virgil A S H Dalm; Dion Paridaens; P Martin van Hagen; Willem A Dik
Journal:  Eur Thyroid J       Date:  2014-12-06

Review 5.  New Therapeutic Horizon of Graves' Hyperthyroidism: Treatment Regimens Based on Immunology and Ingredients From Traditional Chinese Medicine.

Authors:  Qiongyao He; Hui Dong; Minmin Gong; Yujin Guo; Qingsong Xia; Jing Gong; Fuer Lu
Journal:  Front Pharmacol       Date:  2022-04-05       Impact factor: 5.988

6.  Triptolide ameliorates colonic fibrosis in an experimental rat model.

Authors:  Qingsong Tao; Baochai Wang; Yu Zheng; Guanwei Li; Jianan Ren
Journal:  Mol Med Rep       Date:  2015-04-01       Impact factor: 2.952

7.  Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.

Authors:  Jung Min Song; Kalkidan Molla; Arunkumar Anandharaj; Ingrid Cornax; M Gerard O Sullivan; Ameya R Kirtane; Jayanth Panyam; Fekadu Kassie
Journal:  Oncotarget       Date:  2017-04-18

Review 8.  Immunological Aspects of Graves' Ophthalmopathy.

Authors:  Dominika Łacheta; Piotr Miśkiewicz; Alicja Głuszko; Grażyna Nowicka; Maria Struga; Ireneusz Kantor; Krzysztof B Poślednik; Shafaq Mirza; Mirosław J Szczepański
Journal:  Biomed Res Int       Date:  2019-11-12       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.